The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro

Clinical Biochemistry

Volumn 43, Issue 1-2, 2010, Pages 208-213

  Feichtiger, Horst ^a   Wieland, Eberhard ^a   Armstrong, Victor W ^b   Shipkova, Maria ^a  

^a KLINIKUM STUTTGART   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Acyl glucuronide; Antiproliferative effect; Immunosuppression; Mycophenolic acid; Tubulin polymerization

Indexed keywords

ACYLGLUCURONIDE; DRUG METABOLITE; GUANOSINE TRIPHOSPHATE; MYCOPHENOLIC ACID; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; POLYMERIZATION; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; CATTLE; ENZYME INHIBITORS; GLUCURONIDES; GUANOSINE TRIPHOSPHATE; MYCOPHENOLIC ACID; PACLITAXEL; POLYMERS; PROTEIN STRUCTURE, QUATERNARY; TUBULIN; TUBULIN MODULATORS;

EID: 72649096249     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.08.023     Document Type: Article

References (31)

1. Shipkova M., Armstrong V.W., Weber L., et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther. Drug. Monit. 24 (2002) 390-399
2. Kuypers D.R., Vanrenterghem Y., Squifflet J.P., et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug. Monit. 25 (2003) 609-622
3. Ting S.L., Partovi N., Levy R.D., Riggs K.W., and Ensom M.H. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and acyl glucuronide metabolites in stable thoracic transplant recipients. Ther. Drug. Monit. 30 (2008) 282-291
4. Stracke S., Mayer J., Keller F., et al. Mycophenolate sodium (EC-MPS) in kidney transplant recipients (KTx): pharmacokinetics in the early phase post transplantation. Ther. Drug. Monit. 29 (2007) 529 (Abstr.)
5. Bailey M.J., and Dickinson R.G. Acyl glucuronide reactivity in perspective: biological consequences. Chem. Biol. Interact. 145 (2003) 117-137
6. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug. Monit. 25 (2003) 1-16
7. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert. Opin. Drug. Metab. Toxicol. 1 (2005) 505-526
8. Shipkova M., Wieland E., Schutz E., et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 33 (2001) 1080-1081
9. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am. J. Transplant 6 (2006) 121-128
10. Filler G., and Buffo I. Safety considerations with mycophenolate sodium. Expert. Opin. Drug Saf. 6 (2007) 445-449
11. Shipkova M., Beck H., Voland A., et al. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 4 (2004) 2728-2738
12. Asif A.R., Armstrong V.W., Voland A., Wieland E., Oellerich M., and Shipkova M. Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie 89 (2007) 393-402
13. Wieland E., Shipkova M., Schellhaas U., et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. Clin. Biochem. 33 (2000) 107-113
14. Maes B., Oellerich M., Ceuppens J.L., et al. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol. Dial. Transplant. 17 (2002) 923-926
15. Hasche G., Wieland E., Shipkova M., et al. Association between pharmacokinetics (PK), pharmacodynamics (PD), and clinical events under therapy with mycophenolic acid (EC-MPS) in the early phase after kidney transplantation (KTx). J. Am. Soc. Nephrol. 19 (2008) 677A (Abstr.)
16. Heller T., van Gelder T., Budde K., et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am. J. Transplant. 7 (2007) 1822-1831
17. Schütz E., Shipkova M., Armstrong V.W., Wieland E., and Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem. 45 (1999) 419-422
18. Bailey M.J., Worrall S., de Jersey J., and Dickinson R.G. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. Chem.-Biol. Interact. 115 (1998) 153-166
19. Cannel G., Bailey M.J., and Dickinson R.G. Inhibition of tubulin assembly and covalent binding to microtubular protein by valproic acid glucuronide in vitro. Life Sci. 71 (2002) 2633-2643
20. Wilson L., Panda D., and Jordan M.A. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct. Funct. 24 (1999) 329-335
21. Shelanski M.L., Gaskin F., and Cantor C.R. Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. U. S. A. 70 (1973) 765-768
22. Lee J.C., and Timasheff S.N. In vitro reconstitution of calf brain microtubules: effects of solution variable. Biochemistry 16 (1977) 1754-1762
23. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 4350-4354
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
25. Dahms M., and Spahn-Langguth H. Covalent binding of acidic drugs via reactive intermediates: detection of benoxaprofen and flunoxaprofen protein adducts in biological material. Pharmazie 51 (1996) 874-881
26. Downing K.H., and Nogales E. Tubulin and microtubule structure. Curr. Opin. Cell Biol. 10 (1998) 16-22
27. Desai A., and Mitchison T.J. Microtubule polymerization dynamics. Annu. Rev. Cell Dev. Biol. 13 (1997) 83-117
28. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22 (2003) 9075-9086
29. Cannell G.R., Vesey D.A., and Dickinson R.G. Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides. Life Sci. 70 (2001) 37-48
30. Díaz J.F., Barasoain I., and Andreu J.M. Fast kinetics of Taxol binding to microtubules. Effects of solution variables and microtubule-associated proteins. J. Biol. Chem. 278 (2003) 8407-8419
31. Gensburger O., Picard N., and Marquet P. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin. Chem. 55 (2009) 986-993